Skip to main content
. 2019 Aug 10;6(5):927–935. doi: 10.1002/ehf2.12505

Table 3.

Current recommendations for sodium‐glucose cotransporter 2 inhibitor use

Type 2 diabetes and45, 46:
1. Insufficient glycaemic control despite first‐line therapya
2. At high cardiovascular risk
3. Cardiovascular disease
4. Cardiovascular disease and coexisting heart failure or at high risk of heart failure
5. Chronic kidney diseaseb
a

First‐line therapy, metformin and lifestyle modifications.

b

Assuming adequate estimated glomerular filtration rate.